Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150251 | 0.79 | OPRL1 (0.53) | OPRL1SSTR4 | |
| SCHEMBL14440475 | 0.75 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL7699577 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL548100 | 0.74 | OPRL1 (0.45) | OPRL1 | |
| SCHEMBL7705836 | 0.74 | CHRNB4 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL2595669 | 0.72 | CHRNB4 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL7705967 | 0.72 | PDE10A (0.48) | CHRNB2CHRNA4HTR3A | |
| Hydrochloric Acid SCHEMBL16454642 | 0.71 | PDE10A (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12027378 | 0.70 | PDE10A (0.52) | — | |
| SCHEMBL7700960 | 0.69 | PDE10A (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493459-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2016-06-23 | — | — | US | disclosed |
| US-9303028-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140148435-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8691986-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2014-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE2A | CHRNB2 400/4885CHRNA4 282/4885CHRNB4 469/4885 |
| US-20140148435-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE2A | CHRNB2 400/4885CHRNA4 282/4885CHRNB4 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.